Levetiracetam protects against kainic acid-induced toxicity

Life Sciences

Volumn 74, Issue 10, 2004, Pages 1253-1264

  Marini, Herbert ^a,b   Costa, Cinzia ^b   Passaniti, Maria ^a   Esposito, Maria ^a   Campo, Giuseppe M ^b   Ientile, Riccardo ^b   Adamo, Elena Bianca ^b   Marini, Rolando ^b   Calabresi, Paolo ^c   Altavilla, Domenica ^a   Minutoli, Letteria ^a   Pisani, Francesco ^b   Squadrito, Francesco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Kainic acid; Levetiracetam; Oxidative stress

Indexed keywords

BRAIN PROTEIN; ETIRACETAM; GLUTATHIONE; INTERLEUKIN 1BETA; KAINIC ACID; LIPID; MALONALDEHYDE; MESSENGER RNA;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN INJURY; BRAIN LEVEL; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; LIPID PEROXIDATION; MALE; NERVE CELL LESION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN DEPLETION; PROTEIN DETERMINATION; RANDOMIZATION; RAT; SEIZURE;

ANIMALIA;

EID: 9144234719     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.08.006     Document Type: Article

References (31)

1. Altavilla D., Squadrito G., Minutoli L., Deodato B., Bova A., Sardella A., Seminara P., Passaniti M., Urna G., Venuti F.S., Caputi A.P., Squadrito F. Inhibition of nuclear factor κB activation by IRFI 042, protects against endotoxin-induced shock. Cardiovascular Research. 54:2002;684-693.
2. Ben A.Y. Limbic seizure and brain damage produce by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience. 14:1985;375-403.
3. Boutin H., Le Feuvre R.A., Horai R., Asano M., Iwakura Y., Rothwell N.J. Role of IL-1a and IL-1b in ischemic brain damage. Journal of Neuroscience. 15:2001;5528-5534.
4. Calabresi P., Picconi B., Saulle E., Centonze D., Hainsworth A.H., Bernardi G. Is pharmacological neuroprotection dependent on reduced glutamate release? Stroke. 31(3):2000;766-772.
5. Cazevieille C., Safa R., Osborn N.N. Melatonin protects prary cultures of rats cortical neurons from NMDA excitotoxicity and hypoxia/reoxygination. Brain Research. 768:1997;120-124.
6. Cherlyee C.W.J., Thomos P.B. Status epilepticus. Neurologic Clinics. 13:1995;529-548.
7. Coyle T.J., Puttfarken P. Oxidative stress, glutamate and neurodegenerative disorders. Science. 262:1993;689-695.
8. Doble A. The role of excitoxicity in neurodegenerative disease: Implications for therapy. Pharmacology and therapeutics. 81:1999;163-221.
9. Ellman G.L. Tissue sulphydryl groups. Archives of Biochemistry and Biophysics. 82:1959;70-73.
10. Eriksson C., Van Dam A.M., Lucassen P.J., Bol J.G., Winblad B., Schulzberg M. Immunohistochemical localization of IL-1 beta, interleukin 1 receptor antagonist and IL-1 beta converting enzyme/caspase-1 in the rat brain after peripheral administration of Kainic acid. Neuroscience. 93(3):1999;915-930.
11. Gupta Y.K., Briyal S., Chaudhary G. Protective effect of trans-resveratrol against kainic acid-induced seizures and oxidative stress in rats. Pharmacology, Biochemistry, and Behavior. 71(1-2):2002;253-257.
12. Hanon E., Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure. 10(4):2001;287-293.
13. Kim H.C., Jhoo W.K., Bing G., Shin E.J., Wie M.B., Kin W.K., Ko K.H. Phenidone prevents kainate-induced neurotoxicity via antioxidant mechanisms. Brain Research. 874:2000;15-23.
14. Lancelot E., Revaud M.L., Boulu R.G., Plotkine M., Callebert J. Alpha-Phenyl-N-tert-butylnitrone attenuates excitotoxicity in rat striatum by preventing hydroxyl radical accumulation. Free Radical Biology and Medicine. 23(7):1997;1031-1034.
15. Lipton S.A., Rosemberg P.A. Excitatory aminoacids as a final pathway for neurological disorders. The New England Journal of Medicine. 330:1994;613-622.
16. Loscher W., Honack D., Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsivant levetiracetam (ucb L059) in the kindling model of temporal epilepsy. The Journal of Pharmacology and Experimental Therapy. 284:1998;474-479.
17. Lukyanetz E.A., Shkryl V.M., Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 43(1):2002;9-18.
18. May M.J., Ghosh S. Signal transduction trough NF-kb. Immunology Today. 19:1998;81-88.
19. McCulloch J. Excitatory aminoacid antagonists and their potential for the treatment of ischemic brain damage in man. British Journal of Clinical Pharmacology. 34:1992;106-114.
20. Meldrum B.S. Glutamate as a neurotransmitter in the brain. Review of Physiology and Pathology. The Journal of Nutrition. 130:2000;1007-1015.
21. Nakao N., Grasbon-Frodl E.M., Widner H., Brundin P. Antioxidant treatment protects striatal neurons against excitotoxic insults. Neuroscience. 73(1):1996;185-200.
22. Nakao N., Brundin P. Neurodegeneration and glutamate induce oxidative stress. Progress in Brain Research. 116:1998;245-263.
23. Olney J.W. Neurotoxicity of excitatory aminoacids. McGeer E.G., Olney J., McGeer P.L. Kainic acid as a tool in neurobiology. 1978;95-112 Raven Press, New York.
24. Poulain P., Margineanu D.G. Levetiracetam opposes the action of GABA-A antagonists in hypothalamic neurones. Neuropharmacology. 42(3):2002;346-352.
25. Racine R.J. Modification of seizure activity by electrical stimulation: Motor seizure. Electroencephalography and Clinical Neurophysiology. 32:1972;281-294.
26. Ray P.S., Maulik G., Cordis G.A., Bertelli A.A., Bertelli A., Das D.K. The red wine antioxidant resveratrol protects the isolated rat heart from ischemia reperfusion iniury. Free Radical Biology and Medicine. 27:1999;160-169.
27. Scultz J.B., Henshaw D.R., Siwek D., Jenkins B.G., Ferrante R.J., Cipolloni P.B., Kowall N.W., Rosen B.R., Beal M.F. Involvement of free radicals in excitotoxicity in vivo. Journal of Neurochemistry. 64:1995;2239-2247.
28. A neurotransmission and cerebral ischemia. Journal of Neurochemistry. 77:2001;353-371.
29. Turski L. NMDA receptor complex: different sites for regulation and clinical consequences. Drug Research. 40:1990;511-514.
30. Yamada T., Matsumori A., Sasayama S. Therapeutic effects of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomiocarditis virus. Circulation. 89(2):1994;846-851.
31. Wang C.X., Shuaib A. Involvement of inflammatory cytokines in central nervous system injury. Progress in Neurobiology. 67(2):2002;161-172.